Balloon Mitral Valvuloplasty at Very Long Term

With a mean follow up of 15 years, and some patients that survived over 20 years, this study shows that more than 75% of patients with rheumatic mitral stenosis show sustained results with balloon valvuloplasty. Predictors of this excellent long-term outcome are many, but they are determined mainly by age, prior symptoms and valve area obtained after procedure.  

valvuloplastía mitralOver the years, mitral valvuloplasty has remained the preferred treatment for patients with rheumatic mitral stenosis and suitable anatomy.

 

All consecutive patients undergoing balloon valvuloplasty between 1987 and 2010 were included. Primary end-point was a composite of all cause death, need for mitral surgery or repeat valvuloplasty at up to 23 years.


Read also: How to Predict Events in Order to Decide Whether to Revascularize Symptomatic Carotid Artery Stenosis.


In all, 1582 patients were included over the years and success was achieved in 90.9% of the population. I independent predictors of intraprocedural success were left atrial size (OR 0.96, p=0.045), Wilkins score ≤8 (OR 1.66, p=0.045), and age (OR 0.97, p=0.006).

Very long-term follow-up (mean follow up = 15.6 years) was obtained in 79.1% of the population, with 19.1% incidence of the primary end-point. Separately, mortality resulted as low as 0.6%, need for valve surgery, 8.3%, and repeat valvuloplasty, 10%.


Read also: More Evidence For MitraClip in High Risk Patients with Severe Tricuspid Regurgitation.


On multivariable analysis, functional class III-IV (HR 1.62, p<0.001), older age (HR 0.97, p=0.028 and post procedural mitral area ≤1.75 cm² (HR 1.67; p=0.028) were independent predictors of the primary end point.

 

Conclusion

Time goes by and mitral valvuloplasty remains the preferred treatment for patients with rheumatic mitral stenosis and suitable anatomy, given its excellent results even after 20 years.

 

Original Title: Very Long Term Follow-Up After Percutaneous Balloon Mitral Valvuloplasty.

Reference: Rafael A. Meneguz-Moreno et al. J Am Coll Cardiol Intv 2018. Article in press.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...